Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,451 matching trials from the live ClinicalTrials.gov search.
Conditions
Hypoglycemia
Interventions
Norepinephrine Transporter (NET) ligand
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Results available

Electrical Stimulation for Improving Balance in Diabetes

NCT02337218
Conditions
Diabetic Peripheral Neuropathy
Interventions
SENSUS Pain Management System
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes Mellitus, Type 2, Depressive Symptoms, Depression
Interventions
Cognitive Behavioral Therapy, Exercise, Group Discussions - Ongoing Support
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Type 2 Diabetes Mellitus (T2DM), Type 1 Diabetes Mellitus (T1DM), Hyperglycemia
Interventions
Libre 3 Plus Continuous Glucose Monitor, Dexcom G7 Continuous Glucose Monitor
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

NCT04028960
Conditions
Type1diabetes
Interventions
Regular insulin (Humulin-R), intranasal route, SipNose intranasal device
Drug · Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Chronic Kidney Diseases
Interventions
Pioglitazone, Placebo
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
35 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Arlington, Texas • Dallas, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Self-management support education, Connection to Health Interactive Behavior Change Technology, Connection to Health plus Coaching (CTH+C)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 89 Years
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Hypertension
Interventions
Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
11,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Type 1 Diabetes
Interventions
Transition preparation program, Educational materials
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
16 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Diabetes, Hypertension
Interventions
Clinical pharmacist-based intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
4,622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional Results available

Diabetes Disparities: Texting to Extend Treatment (DD-TXT)

NCT04227379
Conditions
Diabetes Mellitus, Type 2
Interventions
Intervention 1- DSMS+, Comparison - DSMS
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Gainesville, Florida • Chicago, Illinois • Bedford, Massachusetts
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
FreeStyle Navigator Continuous Glucose Monitoring System
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Accu-Chek 360° View Blood Glucose Analysis Tool, Accu-Chek Aviva Glucose Meter
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Mobile, Alabama • Pell City, Alabama • Chipley, Florida + 22 more
Conditions
Diabetes Mellitus
Interventions
case management with telemonitoring, usual case management
Behavioral
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Lifestyle Modification
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Type 1 Diabetes (T1D)
Interventions
BREATHE-T1D, HealthEd-T1D
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Washington D.C., District of Columbia
Conditions
Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Interventions
(IRIS-CKD Screening Program): Home Kit, (IRIS-CKD Screening Program): Standard Lab Order
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index

NCT02663661
Conditions
Diabetes Mellitus, Type 1
Interventions
Metabolic Challenge Admission, CGM home test
Procedure · Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 45 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c
Interventions
Data Management and Monitoring
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 84 Years
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 6 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Understand Gaining Access to Blood Glucose Records

NCT02956642
Conditions
Diabetes Mellitus
Interventions
Livongo Health System, iHealth Glucose Meter
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Conditions
Spinal Cord Injuries, Type 2 Diabetes
Interventions
Semaglutide Injectable Product, Placebo
Drug · Other
Lead sponsor
Marzieh Salehi
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Ankle Equinus, Ankle Contracture, Diabetes Mellitus
Interventions
Standard of care, Dynasplint
Other · Device
Lead sponsor
Dynasplint Systems, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Jonesboro, Georgia • Fort Worth, Texas
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Anaheim, California • San Diego, California • Golden, Colorado + 18 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more